Marinus Pharmaceuticals Inc (MRNS)
1.57
+0.09
(+6.08%)
USD |
NASDAQ |
May 07, 16:00
1.57
0.00 (0.00%)
After-Hours: 16:17
Marinus Pharmaceuticals Enterprise Value: 3.984M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 06, 2024 | 3.984M |
May 03, 2024 | 5.632M |
May 02, 2024 | 2.336M |
May 01, 2024 | 3.435M |
April 30, 2024 | 0.1387M |
April 29, 2024 | -0.4106M |
April 26, 2024 | -0.1359M |
April 25, 2024 | 0.688M |
April 24, 2024 | 1.787M |
April 23, 2024 | 1.787M |
April 22, 2024 | 3.709M |
April 19, 2024 | -1.509M |
April 18, 2024 | 0.1387M |
April 17, 2024 | 1.787M |
April 16, 2024 | -11.40M |
April 15, 2024 | -5.904M |
April 12, 2024 | 335.77M |
April 11, 2024 | 357.74M |
April 10, 2024 | 367.08M |
April 09, 2024 | 383.01M |
April 08, 2024 | 373.12M |
April 05, 2024 | 351.15M |
April 04, 2024 | 399.49M |
April 03, 2024 | 400.59M |
April 02, 2024 | 409.92M |
Date | Value |
---|---|
April 01, 2024 | 415.42M |
March 28, 2024 | 416.66M |
March 27, 2024 | 406.27M |
March 26, 2024 | 402.99M |
March 25, 2024 | 410.64M |
March 22, 2024 | 404.09M |
March 21, 2024 | 415.02M |
March 20, 2024 | 416.66M |
March 19, 2024 | 430.86M |
March 18, 2024 | 415.56M |
March 15, 2024 | 435.78M |
March 14, 2024 | 411.74M |
March 13, 2024 | 438.51M |
March 12, 2024 | 429.77M |
March 11, 2024 | 386.06M |
March 08, 2024 | 406.27M |
March 07, 2024 | 400.81M |
March 06, 2024 | 416.11M |
March 05, 2024 | 427.58M |
March 04, 2024 | 443.98M |
March 01, 2024 | 464.74M |
February 29, 2024 | 441.79M |
February 28, 2024 | 461.04M |
February 27, 2024 | 468.69M |
February 26, 2024 | 468.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-11.40M
Minimum
Apr 16 2024
599.59M
Maximum
Jul 09 2021
249.29M
Average
237.06M
Median
May 31 2023
Enterprise Value Benchmarks
Ligand Pharmaceuticals Inc | 1.119B |
Soligenix Inc | -0.9081M |
Actinium Pharmaceuticals Inc | 179.23M |
Macrogenics Inc | 792.21M |
ADMA Biologics Inc | 1.656B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -41.77M |
Revenue (Quarterly) | 7.19M |
Total Expenses (Quarterly) | 42.63M |
EPS Diluted (Quarterly) | -0.74 |
Gross Profit Margin (Quarterly) | 87.66% |
Profit Margin (Quarterly) | -580.9% |
Earnings Yield | -167.5% |
Normalized Earnings Yield | -167.52 |